Kuppermann, Baruch D.Goldstein, MichaellaMaturi, Raj K.Pollack, AyalaSinger, MichaelTufail, AdnanWeinberger, DovLi, Xiao-YanLiu, Ching-ChiLou, JeanWhitcup, Scott M.2016-04-192016-04-192015-09Kuppermann, B. D., Goldstein, M., Maturi, R. K., Pollack, A., Singer, M., Tufail, A., ... & Whitcup, S. M. (2015). Dexamethasone Intravitreal Implant as Adjunctive Therapy to Ranibizumab in Neovascular Age-Related Macular Degeneration: A Multicenter Randomized Controlled Trial. Ophthalmologica, 234(1), 41-55. doi: 10.1159/000381865https://hdl.handle.net/1805/9343Purpose: To evaluate the efficacy and safety of dexamethasone intravitreal implant 0.7 mg (DEX) as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration (nvAMD). Procedures: This was a 6-month, single-masked, multicenter study. Patients were randomized to DEX implant (n = 123) or sham procedure (n = 120) and received 2 protocol-mandated intravitreal ranibizumab injections. The main outcome measure was injection-free interval to first as-needed ranibizumab injection. Results: DEX increased the injection-free interval versus sham (50th percentile, 34 vs. 29 days; 75th percentile, 85 vs. 56 days; p = 0.016). 8.3% of DEX versus 2.5% of sham-treated patients did not require rescue ranibizumab (p = 0.048). Visual acuity and retinal thickness outcomes were similar in DEX and sham-treated patients. Only reports of conjunctival hemorrhage (18.2 vs. 8.5%) and intraocular pressure elevation (13.2 vs. 4.2%) were significantly different in the DEX versus the sham treatment groups. Conclusion: DEX reduced the need for adjunctive ranibizumab treatment and showed acceptable tolerability in nvAMD patients.enAttribution-NonCommercial 3.0 United Statesage-related macular degenerationchoroidal neovascularizationcorticosteroidArticle